TOP STORIES

Quality Novo Nordisk's Bloomington crisis deepens: Incyte becomes fourth company hit by CRL tied to former Catalent site

Incyte disclosed on March 9 that the FDA issued a complete response letter rejecting its PD-1 inhibitor Zynyz as a first-line non-small cell lung cancer treatment—not on efficacy or safety grounds but due to inspection findings at the Novo-owned Bloomington, Indiana fill-finish facility. This marks the fourth biopharma company to suffer regulatory consequences tied to quality problems at the former Catalent plant, following Regeneron (multiple Eylea HD CRLs beginning 2023), Scholar Rock (apitegromab BLA rejection, September 2025), and Ferring Pharmaceuticals. Incyte's Phase III Pod1um-304 trial had demonstrated a 25% reduction in death risk for Zynyz plus chemotherapy in metastatic NSCLC—a commercially significant indication now delayed by a manufacturing site the company does not own or operate.

The Bloomington site's regulatory history is now extensive. An FDA inspection from June–July 2025 uncovered contamination by mammalian hair in or around vial stopper regions, bacterial contamination, aborted media fill runs without documented root cause investigations, and reliance on pre-shipment "tailgate" samples rather than on-site component sampling. In October 2025, STAT News reported the FDA classified the site as "official action indicated"—its most severe post-inspection designation. The November 2025 warning letter followed, with Xtalks noting the FDA expressed concern that contaminated product continued to be released even after the Novo acquisition.

Client responses: BioSpace reported in December 2025 that both Regeneron and Scholar Rock have been securing alternative fill-finish capacity. Scholar Rock completed tech transfer to a new provider in early 2026 and plans to include the alternate site in an approval refiling this year. Regeneron received belated FDA approval for high-dose Eylea after resolving some manufacturing issues but is still working on prefilled syringe approval tied to the Bloomington site. Incyte's path forward will depend on whether it, too, pivots to an alternate manufacturer or awaits a successful FDA reinspection of the Bloomington facility.

Regulatory FDA and industry reach preliminary agreement on pre-submission facility meetings under PDUFA VIII—a direct response to the CRL wave

Against the backdrop of mounting manufacturing-related drug rejections, BioSpace reported on March 10 that FDA and industry negotiators have reached general agreement on the scope of pre-submission facility meetings designed to reduce facility-related CRLs under the next PDUFA reauthorization (PDUFA VIII, covering fiscal years 2028–2032). The February meeting minutes published by FDA show the agency agreed that these meetings could cover prior production site inspection history, novel or unique process elements relevant to the drug candidate, risk mitigation strategies, and "supply chain nodes"—groups of facilities that may support a future application.

However, the FDA pushed back on industry proposals to include alternative tools to assess facility information, inspection scheduling, and overall manufacturing process discussions within the meeting scope. The agency said these topics should be handled through existing regulatory meeting types. Notably, while excluding manufacturing schedules from the formal meeting agenda, the FDA acknowledged that industry "may provide awareness of manufacturing schedules"—a nod to industry complaints raised during PreCheck program meetings in late 2025 that aligning production schedules with pre-approval inspections forces companies to keep production suites idle and delays submissions.

Capacity Lilly commits $3B to China for orforglipron manufacturing—revealing the dual-track reality of pharma's geographic strategy

Eli Lilly announced on March 11 that it will invest $3 billion in China over the next decade, centered on building localized oral solid dosage manufacturing capacity for orforglipron, its once-daily small-molecule GLP-1 agonist currently under review by China's National Medical Products Administration. The investment expands Lilly's Suzhou production facility (established 1996) and adds oral manufacturing capacity in Beijing. In parallel, Lilly signed a $200 million partnership with Pharmaron, a Beijing-based CDMO, to build production and development capabilities for orforglipron and future treatments. The move brings Lilly's total China investment to nearly $6 billion.

The announcement comes as Lilly simultaneously executes a $50 billion U.S. manufacturing expansion that includes four new domestic plants, at least three earmarked for GLP-1 production. Lilly has already built approximately $550 million in orforglipron inventory in the U.S. ahead of a potential FDA approval expected in Q2 2026. As BioPharma Dive noted, U.S. and European drugmakers are deepening China investment to supply the local market even as tariff policy pushes reshoring of U.S.-bound production. GlobalData forecasts orforglipron global sales of $13 billion by 2031 if approved.

REGULATORY & COMPLIANCE

• Quality FDA warning letter to Novo Nordisk's Plainsboro, NJ headquarters (dated March 5, 2026) cites systemic failures in adverse event reporting for products including semaglutide, liraglutide, and nedosiran. PharmExec reported three core violations: internal procedures allowing ADE rejection if reporters deemed events drug-unrelated (inconsistent with FDA rules); requiring reporter consent before follow-up on serious cases; and inadequate medical review timelines. The FDA cited unreported patient deaths and suicidal ideation among examples. FiercePharma noted the letter explicitly states the FDA has "serious concerns about the scope and impact" across Novo's entire product portfolio.
• Regulatory PDUFA VIII pre-submission facility meetings scope has been largely agreed between FDA and industry. The FDA's November 2025 proposal and subsequent February 2026 meeting minutes outline meetings covering facility inspection history, novel process elements, risk reduction strategies, and supply chain node assessment. The current PDUFA VII agreement expires September 2027; the new framework would apply from FY2028–2032.
• Regulatory API Innovation Center released its 2026 white paper (March 10), "From Fragility to Resilience," documenting that over 200 prescription medicines are currently in shortage nationwide and arguing these represent symptoms of structural supply chain fragility—not isolated disruptions. The nonprofit, which uses public-private funding to develop continuous manufacturing processes for critical generic APIs, has created a continuous process for lomustine that Apertus Pharmaceuticals is adopting at a Missouri facility, with a $9.5 million state grant supporting the work.
• Quality Novo's cumulative regulatory exposure now spans: the Bloomington, IN warning letter (cGMP, November 2025); the Plainsboro, NJ warning letter (PADE reporting, March 2026); untitled letters for Ozempic and Wegovy marketing; and at least four client CRLs tied to the Bloomington site. Novo's March 10 statement expressed confidence in resolving all matters but acknowledged the breadth of regulatory communications is unusual.

CAPACITY & SUPPLY CHAIN

• Capacity AbbVie announced a $380 million investment in North Chicago, IL to expand API manufacturing, with construction beginning spring 2026 and facilities operational by 2029. The project adds 300 jobs and represents further progress against AbbVie's $100 billion decade-long U.S. commitment. AbbVie is also acquiring a device manufacturing facility in Arizona and evaluating additional state-level manufacturing investments for 2026 announcements.
• Capacity Eli Lilly's global manufacturing footprint now spans a $50 billion U.S. program (four new plants, three confirmed for GLP-1 production, $27 billion committed in February 2025 alone) and the newly announced $3 billion China program centered on Suzhou and Beijing. Lilly reported a 45% revenue surge in 2025 driven by $13.5 billion in Zepbound and $23 billion in Mounjaro sales, providing the cash flow to fund parallel geographic buildouts.
• CDMO Continuous manufacturing adoption is advancing beyond pilot stage but remains constrained by upfront capital costs, per BioSpace's March 10 report. Eli Lilly, GSK, J&J, and Vertex have adopted continuous processes for select drug substances and products, but generic manufacturers—where the economics are tightest—cannot justify the investment without external subsidies. The API Innovation Center's model of using blended public-private funding to absorb upfront costs and then transfer processes to manufacturers offers a potential template for scaling adoption.
• Peptide Semaglutide patent expiration in China this month opens the market to Chinese generics, intensifying the competitive urgency behind both Novo's local production plans and Lilly's orforglipron manufacturing investment. For CDMOs serving the Chinese market, generic semaglutide production represents a significant new peptide manufacturing opportunity, while Lilly's small-molecule approach via Pharmaron represents a fundamentally different production paradigm.

WHAT TO WATCH NEXT

Bloomington reinspection and client migration timelines

The critical near-term question is whether the Bloomington facility can pass an FDA reinspection in time to unblock pending drug approvals—or whether affected clients will complete tech transfers to alternate sites faster than Novo can remediate. Scholar Rock's alternate fill-finish provider is already in tech transfer, with plans to include the new site in a 2026 refiling. Incyte's response strategy is not yet public. Meanwhile, the FDA's warning letter recommended that Novo review quality oversight at its other acquired Catalent facilities (Anagni, Italy and Brussels, Belgium)—a signal that regulatory scrutiny could widen beyond Bloomington. If a reinspection fails or is delayed, the pressure on alternative fill-finish CDMO capacity will intensify, benefiting providers like Simtra, Grand River Aseptic Manufacturing, and Baxter BioPharma Solutions.

PDUFA VIII negotiations—from scope agreement to legislative text

The pre-submission facility meeting framework needs to move from conceptual agreement to specific legislative language before PDUFA VIII's September 2027 implementation deadline. Open questions include how many meetings per application will be permitted, whether the meetings carry any binding commitments from FDA, and whether the framework will apply retroactively to applications already in review when PDUFA VIII takes effect. Industry will push for broader scope; FDA will push for focused discussions that don't become de facto pre-approval inspections. The final terms will shape whether CMC risk management becomes a formal, auditable component of drug development planning.

Lilly's China-U.S. manufacturing arbitrage—and tariff implications

Lilly's $3 billion China commitment, announced the same month that mandatory MFN pricing models are being finalized, raises policy questions. The investment is structured to serve the Chinese market locally (not to export back to the U.S.), but the optics of building Chinese manufacturing capacity while claiming tariff exemptions through U.S. investment pledges will draw scrutiny from policymakers tracking pharmaceutical supply chain geography. Watch for whether other companies follow Lilly's explicit dual-track model or maintain the current convention of announcing U.S. and international expansions separately to avoid the juxtaposition.